Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors
Phase 1/2
49
about 3.6 years
18+
3 sites in CT, FL, OK
What this study is about
This trial is testing the safety and side effects of a new drug combination called entinostat and ZEN003694 in people with advanced or resistant solid tumors. The goal is to find the best dose of this treatment.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take BET Bromodomain Inhibitor ZEN-3694
- 2.Take Entinostat
- 3.Undergo Computed Tomography
- +1 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Maximum tolerated dose (MTD) (Phase Ib), Objective response rate (ORR) (Phase II)
Secondary: Duration of response, Overall survival, Progression free survival, Response rate (RR) in patients with advanced/progressive pancreatic cancer (Phase II)
imaging, biopsy
Oncology